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Objective: To determine epidemiology and antimicrobial susceptibility patterns of Vibrio (V.) 
cholerae O1 biotype EL Tor in summer outbreak of 2008 in Iran. Methods: Stool samples were 
collected from patients suspected to have cholera admitted to hospitals and clinics. Specimens 
examined by conventional bacteriological methods. All isolates were sent to cholera reference 
laboratory for further confirmation, stereotyping and susceptibility testing. Results: A total of 220 
patients were diagnosed as cholera. All cases confirmed by Iranian reference health laboratory. One 
hundred ninety nine of 220 V. cholerae serotypes were Inaba and 21 serotypes were Ogawa. All 
cases were reported from thirteen provinces. The majorities of cases were from Tehran, Qum and 
Zahedan provinces with 56, 26 and 25 cases respectively. 24(11%) of patients were under 15  years 
old and 196 ( 89%)  of patients were older than 15 years.149 (68% ) of patients were male and 71 (32 
%) were female. 129( 59%) of patients  had Iranian nationality,79 (36.5% ) were  from Afghanistan 
and, 12 ( 5% ) were from Pakistan. All isolates were resistant to co-trimoxazole, nalidixic 
acid, furazolidone, and intermediate to chloramphenicol and were susceptible to tetracycline, 
ciprofloxacin, and erythromycin. Conclusion: Our study reveals that in recent outbreak caused 
by V. cholerae EL Tor serotype Inaba is the predominant serotype. All isolates are resistant to co-
trimoxazole, nalidix acid and furazolidon.
1. Introduction
  Vibrio (V.) cholerae is a gram- negative comma shaped 
bacterium that causes cholera in human. Cholera is a wide-
spread and severe disease and a global threat worldwide 
[1]. The main symptom of cholera is the production of 
life threatening watery diarrhea with varying degree of 
dehydration ranging from none to sever [2]. Since 1817, six 
pandemic have been reported and the seventh one is in 
progress [3]. Strains of V. cholerae belonging to serogroup O1 
biotype El Tor and serogroup O139 have been described the 
causative agents of disease[3]. V. cholerae O139 responsible 
for non-O1 serotype isolated in 1992 in southern India and 
then spread rapidly up and down the coast of the Bay of 
Bengal reaching Bangladesh in December 1992. However, 
V. cholerae serogroup O1 still is the most common cause of 
cholera epidemics. Cholera is an endemic disease in Iran 
and is common in summer and early month of autumn. The 
causative serogroup in our country is O1 and we did not 
have any report for isolation of O139 serogroup in recent 
outbreaks [4-6].
  The survival of V. cholerae in aquatic environment, and 
the potential role of the reservoir in subsequent disease 
outbreaks have been described in several studies [2]. 
Cholera disease have Owen epidemiologic features. Study 
and reconnection of different age groups at risk depends 
on epidemiologic pattern, causative serogroup, serotype, 
and source of infection. Drug resistance patterns are 
important parameters for designing preventative measures. 
The Islamic republic of Iran is at risk of cholera outbreaks 
especially spreading from neighboring country. The Center 
for disease control and prevention of Ministry health 
reported 12 epidemics of cholera since 1965. The recent 
epidemic occurred in 2005 with 1133 cases and 11 cases 
of death[2, 7, 8]. The aim of this study was to determine 
epidemiology and antimicrobial susceptibility patterns of 
Vibrio cholerae O1 biotype EL Tor in summer of 2008 in 
Iran.
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2. Materials and methods
  Fecal specimens (stool or rectal swabs) were collected 
from patients that were admitted to hospital and clinics 
because of suspected cholera. Specimens were examined 
by conventional bacteriological methods. Briefly alkaline 
peptone water (APW) was used as an enrichment broth, 
and thiosulfate citrate bile salts sucrose agar (TCBS) as a 
selective agar medium. APW tubes were incubated at 37 
℃ for 6 to 8 hours. Subculture from APW was done on 
TCBA agar. All plates were incubated at 37 ℃ for 18-24h. 
Suspected sucrose fermenting colonies which were oxidase 
positive, indol positive and morphologically resembling to V. 
cholerae were identified biochemically and serologically[9, 
10]. Serotype identification was based on agglutination test by 
using polyvalent and monovalent antisera as recommended 
by manufacture (Mast Diagnostic Group UK). A positive 
reaction with polyvalent antsera was considered as V. 
cholerae O1 isolate. Agglutination reaction with Inaba and 
Ogawa antisera were used for further serotyping.   
 All isolates were sent to cholera reference laboratory for 
confirmation, and susceptibility testing. Antimicrobial 
susceptibility testing was performed by disk diffusion 
methods as recommended by clinical laboratory standard 
institute (CLSI). Demographic data including clinical status, 
age, sex collected from questioner forms .The antimicrobial 
drugs testes included ampicillin (AM),  co-trimoxazole 
(SXT), ciprofloxacin (CIP), tetracycline (TC), erythromycin 
(EM), choleramphenicol (C), cefexime (CFM) furazolidone 
(F) and  nalidixic acid (NA). The E-test MIC (AB Biodisk , 
Solna, Sweden ) method were used for detection of minimal 
inhibitory concentration (MIC)  for erythromycin[11].
3. Results
   From June to November 2008 all suspected patients of 
cholera were reported to the Center for Disease Control 
and Prevention of Ministry of Health and education. A total 
of 220 patients were clinically diagnosed as cholera with 
laboratory confirmation. Of the 220 isolates, 199 serotypes 
were Inaba and 21 serotypes were Ogawa. 
  The majority cases were from 3 of the 13 provinces where 
the data were collected from and included, Tehran (56), 
Qum (26) and Zahedan (25) cases. Of the 220 patients, 
11% (24) were under 15 years old and 89% (196) were 
above 15years old. Of 220 patients, 149 (68%) were male 
and 71 (32%) were female. 129 (59%) of patients had 
Iranian nationality, 79 (36%) were from Afghanistan and 12 
(5%) were from Pakistan. All isolates were resistant to co-
trimoxazole, nalidixic acid, furazolidone and intermediate 
resistance to chloramphenicol. All isolates were susceptible 
to tetracycline, ciprofloxacin, and erythromycin. MIC for 
erythromycin ranged between 1-1.5 滋g/mL.   
   The antimicrobial  results and pulse f ield gel 
electrophoresis (PFGE) showed that all isolates had the 
same epidemiology and susceptibility patterns (Figure 1-4).
Figure 1. Reported cholera from unverisities.
Figure 2. Age of cholear patients.
Figure 3. Nationality of patients.
Figure 4. Weekly reported cholera cases in summer of 2008 in Iran.
4. Discussion
   This is the second report of increased isolation of   
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of Inaba serotype from Iran. The first report was in 2005, 
when 1 104 cases of isolation reported [5,12]. Recent 
studies from Pakistan our eastern neighbor also showed an 
increased isolation of Inaba serotype [13]. The predominance 
of cholera due to V. cholerae O1 serotype Inba was also 
reported from India in recent years [14-16]. It needs molecular 
analysis such as PFGE to understand the widespread 
emergence of V. cholerae O1 serotype in different countries. 
Molecular studies on outbreak of 2005 in our country 
revealed similarity among V. cholerae O1 Inaba serotypes 
isolates. However there is not enough data in other countries 
for detection of origin of recent outbreaks.
  It is assumed that the present Inaba serotype might have 
evolved from pre-existing V. cholerae O1 Ogawa isolates. 
V. cholerae O1 strains are known to interconvert and to 
switch between the two known serotypes, Ogawa and Inaba. 
Serotype switching may be related to immune pressure on 
the prevailing serotype as suggested by the observation of an 
epidemic in Latin America in 1991[16]. 
  Data generated in the present study revealed that 
tetracycline, one of the main antimicrobials agent used 
for cholera treatment, was the most effective antibiotics. 
Our previous study in 2005 outbreak also showed that 
all isolated stains of V. cholerae were susceptible to 
tetracycline [7]. In our study all strains of V. cholerae that 
were susceptible to tetracycline were also susceptible to 
doxycycline. Doxycycline in our country is used as the first-
line drug for treatment of cholera. Among third generation 
of cephalosporins, cefexim was effective against all isolates 
of V. cholerae, however this antibiotic is expensive and 
its supply is very limited. In contrast to other studies on 
diarrheal etiologies in our country that reported frequent 
resistance to ampicillin, all isolates of V. cholerae were 
susceptible to ampicillin. This antibiotic is an alternative 
drug for treatment of cholera in children, which all 
isolates are resistant to furazolidin. Among furoquinolnes, 
ciprofloxacin was the most effective antibiotic; however a 
significant limitation of fluoroquinolnes is their controversial 
use in children.    
  Resistance to co-trmoxazole was similar to results of 
prior study. The 100% resistance rate of V. cholerae to 
co-trmoxazole is due to widely use of this antibiotic for 
treatment of other diarrheal and urinary tract infections. 
Resistance of V. cholerae to nalidixic acid may due to 
widely use of this antibiotic in treatment of other infectious 
disease such as urinary tract infections and gastroenteritis. 
Intermediate resistance of V. cholerae to chloramphenicol 
is also notable, which make its usage limited. This can 
be partially explained by its frequent usage as a first 
line treatment for sever infectious diseases especially in 
children.
   In general data obtained in this study and comparison of 
the results with that of our previous study in 2005, suggest 
that there is one main colonial strain circulating in recent 
outbreaks in our country .This hypothesis is confirmed also 
by molecular studies.
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